Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Ozempic Maker Novo Nordisk Lowers 2025 Outlook After Tepid Results

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Novo Nordisk lowers full-year profit guidance in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

Novo Nordisk A/S: Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the ...

Novo Nordisk Q3 sales in line with forecasts in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter

COPENHAGEN () -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a ...
Taiwan News

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the ...